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INTRODUCTION
In Estelle v. Gamble 1, the United States Supreme Court recognized that "[a]n inmate
must rely on prison authorities to treat his medical needs; if the authorities fail to do so,
those needs will not be met." The Court held that the State has a constitutional obligation
under the Eighth and Fourteenth Amendments to provide adequate medical care to those
whom it has incarcerated. 2 However, Estelle did not set forth exactly what qualifies as
"adequate" medical care. Does this mean that the State must supply the latest standard
of medical care? This paper will address the seriousness of Hepatitis C if left untreated;
the current standard of medical care provided for the treatment of Hepatitis C, which
has a cure rate of ninety percent; and whether or not the State is required to supply
that treatment to prison inmates to satisfy the constitutional obligations of providing
adequate medical care.
Today courts are reviewing class action lawsuits that have been filed by prison inmates
seeking the current standard of medical care for their Hepatitis C. 3 In reaching a ruling,
the courts will need to determine whether the Department of Corrections is required
to provide inmates the new standard of care for the treatment of Hepatitis C, which
is a very costly drug. This new wave of drugs for the treatment of Hepatitis C can
cost anywhere from $89,000 to a discounted rate of $40,000 per inmate, which could
potentially undermine the budgets of the Department of Corrections nationwide. 4
This article will first briefly set forth a general background of Hepatitis C, including
what it is, how it is diagnosed and treated. Part II of this article will explain the current
standard of medical care and the treatment developments. Part III of this article will
address whether or not the Department of Corrections should be constitutionally
required to treat all inmates currently diagnosed with Hepatitis C with the latest
developed drugs, based off of three pending class action lawsuits brought by prisoners
against the state Department of Corrections. Part IV of this article will discuss possible
policy implications by examining the Wyoming Department of Corrections Policies,
and finally this article will conclude by finding that absent a diagnosis of an advanced
stage of Hepatitis C, the states' Department of Corrections should not be mandated to
provide this costly treatment to inmates.

1

Estelle v. Gamble, 429 U.S. 97, 103 (1976)
care from the corrections aep1art1ner11)
2

Id. at l 04. See also

that inmate did not receive proper medical

v. Williamson, 191N.C.487, 490 (1926).

3

See Chimenti v.
Dept. of Corrections, No. 15-3333, 2016 U.S. Dist. LEXIS 36682
(E.D. Pa. Mar. 21, 2015); Paszko v. O'Brien, No. l-15-cv-12298-NMG (D. Mass. June 10, 2015);
v. Minnesota Dept. of Corrections, No. 15-cv-02210-PJS-BRT (D. Minn. filed May l, 2015).
4

SAM

PK. COLLINS, Prisoners in lvlassachusetts
(June 16, 2015), httT1'"/ith1nlCT1rnDTle"

PROGRESS

treatments to be at rates of 90% or more).
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I. BACKGROUND
A. What is Hepatitis C?

First, it is important to understand what Hepatitis C is and how it affects the body.
Hepatitis C is the most common chronic blood-borne infection in the United States with
about 4 million people diagnosed with chronic Hepatitis C. 5 This disease is caused by
a virus that infects and inflames the liver. 6 For some people the infection lasts only a
short time, and the body is able to clear the virus.7 However, most people infected with
Hepatitis C develop chronic Hepatitis C. 8 Chronic Hepatitis C is a long-term illness that
happens when the virus stays in the body. 9 The majority of people who have chronic
Hepatitis C are not even aware that they carry the disease because symptoms often
do not develop for many years until the infection has started to damage their liver. 10
According to the Center for Disease Control and Prevention (CDC), nearly eight in ten
untreated people will remain infected for life. 11 CDC provides annual reports that break
down the number of people infected into age groups. 12
The largest category of those infected fall into the baby boomer era (those born from
1946 to 1964 ). 13 The CDC states that this may be due to these people becoming
infected before the virus was identified and blood was tested for the disease. 14
According to the United States Census Bureau, there are currently 76.4 million baby
boomers living in the United States, 15 which increases the importance of testing
individuals in this category. 16 The CDC has even stated that baby boomers are five
times more likely to have Hepatitis C. 17 Additionally, the CDC reports that there has
been a steady increase in the number of cases reported since 2009, at least through

5 FDA Consumer Updates, Faster, Easier
Hepatitis C, http://>vww.fda.gov/ForConsumers/
ConsmnerUpdates/ucm405642.htm (last visited Nov. 13, 2015).
6 Id.
7

Nat'! Ctr. for Biotechnology Info., US. Nat']
of Med., Hepatitis C, http://ww·vv.ncbi.nlm.
nih.gov/pubmedhealth/PMHT0022399/
visited Sept 12, 2015)[hereinafter NIH Hepatitis Cl
s Id.
9
Nat'l Ctr for Biotechnology Info., US. Nat'! Library of Med., Chronic Hepatitis,
nlmnih.gov/pubmedhealth/PMHT0023081/
visited Sept 15, 2015).
w Id.
11

Id. (causing those people to

chronic Hepatitis C).

12

See, e.g, Center for Disease Control and Prevention,
United
States, 2013, http://www.cdc.gov/hepatitis/statistics/2013 surveillance/commentary.htm#hepatitisC
(last visited Sept l 0, 2015) [hereinafter CDC Surveillance].
t3 Id.
14

Id

15

Kelvin Pollard & Paila Scommegna, POPULATION REFERENCE BuREAU, Just How
Boomers Are There, http://wwvv.prb.org/Publications/A1iicles/2002/
JustHowManyBabyBoomersAreThere.aspx
visited Sept 15, 2015).
16

Center for Disease Control and Prevention,
C,
Saves Lives,
(May 2013)
(noting that many baby boomers became
infected before the dangers of Hepatitis C were well knov\111).
17 ld.
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the 2013 reports. 18 Moreover, in 2013, forty-one states reported an estimate of
29, 718 cases of acute Hepatitis C across the United States. 19
If Hepatitis C is left untreated, over time (up to twenty years or longer in some people)
the infection could damage the liver. 20 Untreated Hepatitis C could also cause cirrhosis
(scarring of the liver that makes the liver not function correctly), liver cancer, liver
failure, and potentially even death. 21 Hepatitis C is a leading cause of liver cancer and
the most common reason for liver transplants in the United States. 22 Recent studies
reflect about 15,000 deaths in the United States each year are due to Hepatitis C. 23

B. How is Hepatitis C Transmitted?
Hepatitis C is an infectious and contagious liver disease that spreads through bloodto-blood contact with an infected person. 24 Hepatitis C may be spread by sharing
razors, toothbrushes, needles, syringes or other equipment that is used to inject
drugs. 25 Individuals may also be put at risk simply by getting a tattoo with unsterilized
tools, receiving a blood transfusion prior to 1992, or even being born to a mother
infected with Hepatitis C. 26 Other occupational hazards may present risks to exposure,
especially in the medical and dental fields. 27 Finally, adults that are incarcerated in
correctional facilities are at risk because many inmates already have Hepatitis C. 28 It
can be difficult to eliminate exposure because bleaching, boiling, heating with a flame,

18

See CDC Surveillance, supra note 12.

19

Id. (The CDC's National Notifiable Disease Surveillance System (NNDSS), viral hepatitis casereports are received electronically from state health departments via CDC's National Electronic
Telecommnnications System for Surveillance (NETSS), a computerized public health surveillance
system that provides the CDC with data regarding cases on a weekly basis. Although surveillance
infrastructure is in place, reports are not submitted by all states. As noted in a recent report from
the Institute of Medicine (Institute of Medicine, Hepatitis and liver cancer: a national strategy
for prevention and control
B and C. Washington, DC: The National Academies Press,
2010: 1-232. ), surveillance capacity to monitor viral hepatitis is limited at the state and local levels,
resulting in underreporting. To account for under-ascertainment and under-reporting, an estimation
method was developed in 2011 to better quantify the number of new cases of hepatitis A, B, and C
from the actual number of cases reported for each disease. (Klevens RM, Liu SJ, Roberts H, Jiles
RB, Holmberg SD. Estimating acute viral hepatitis infections from nationally reported cases. Am J
Public Health. 2014;104(3):482-7).)
20
21

See NIH Hepatitis C, supra note 7.
Id.

22

Id.

23

Id.

24

U.S. DEP'T OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION,
HEPATITIS c AND INCARCERATION (Oct. 2013), http://~rww.cdc.gov/hepatitis/HCV/PDFs/
HepCincarcerationFact Sheet. pdf [hereinafter HEPATITIS c AND INCARCERATION].
2s

Id.

26

Id.

27

Id.

28

Id. (stating that eliminating Hepatitis C exposure is difficult in general, but especially so in
prisons with high volume of infected persons).
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or using a common cleaning fluid (such as alcohol or peroxide) is not strong enough
to kill the virus. 29
The CDC breaks down the 2013 reported risk exposure and behavior cases and their
transmission into the following groups: (1) 61.6% indicated use of injection drugs;
(2) 16.4% of males indicated sex with another male; (3) 18.4% reported sexual
contact with a person confirmed or suspected to have Hepatitis C; 30 ( 4) 1 % reported
occupational exposures, including employment in a medical, dental, or another field
involving contact with human blood; (5) 12.2% indicated having surgery; and (6)
7.7% indicated having an accidental needle stick or puncture. 31 This breakdown is
only derived from reported cases. 32
Most people do not notice any symptoms of Hepatitis C for many years until the
virus begins to damage their liver. 33 When symptoms of Hepatitis C do appear, they
often appear as symptoms caused by common illnesses and go undiagnosed until they
manifest as liver damage. 34 These symptoms include: fever, upset stomach and nausea,
diarrhea, loss of appetite, feeling exhausted, yellowed eyes and skin called "jaundice",
swelling of the belly, easy bruising, and taking longer for bleeding to stop. 35
C. Information on Testing for Hepatitis C

According to the CDC, the only way to know if someone has Hepatitis C is to get
tested. Doctors use a blood test, called a Hepatitis C Antibody Test, which will identify
antibodies to the virus and reveal if a person has ever been infected with Hepatitis C. 36
Antibodies are chemicals released into the bloodstream when someone gets infected. 37
Test results may take anywhere from a few days to a few weeks to come back, and can
either produce a non-reactive or negative result (meaning that a person does not have
Hepatitis C, or that they have not been infected for a period long enough to be detected)
or a reactive/positive result (meaning that antibodies were found in the blood). 38A
reactive antibody test does not necessarily mean a person still has Hepatitis C. 39 Once
a person has been infected, they will always have antibodies in their blood, even if they

c AND INCARCERATION, supra note 24.

29

See

30

See CDC Surveillance, supra note 12, at
Id.

31

HEPATITIS

4.6a.

Id.
33

See NlH

C,

note 7.

Id.
35

Robin Madell,
Reviewed
8, 2016, What Are the Symptoms and Warning Signs
C?, nrtjJ:lrW"Ww.11ea.1m1me.
visited on Jan. 30, 2017); See qer1en11Lv
AND lNCARCERAf!ON, supra note 24.
36

Hepatitis C and Baby Boomers
(Jan. 27, 2015),
Id.
39

Id.
Id.
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have cleared the Hepatitis C virus. 40 A reactive antibody test requires an additional,
follow-up test to determine if a person is currently infected with Hepatitis C. 41
D. The Prevalence of Hepatitis C in Correctional Facilities
A significant number of people who enter the prisons and jails are already suffering
from serious health conditions. 42 The correctional system becomes responsible for
an inmate's health care and treatment during incarceration. 43 It is pertinent to note
the difference between jails and prisons to better understand the duration that an
inmate may be under the care and control of the facility. 44 Because there is a rapid
turnover within the incarcerated population, the funding for correctional health and
prevention services often limits the correctional system in providing both curative and
preventative care. 45
According to the CDC, in 2013, there were 2.2 million people in the United States jails
and prisons, and one in three had Hepatitis C. 46 However, a 2014 report indicates that
the rate of infected inmates "declined to 17.4%"47 , with those diagnosed with chronic
infection "estimated to be between 12 and 35%."48 The inmate population diagnosed
with Hepatitis C represents about one-third of the total cases in the United States. 49
The CDC notes that Hepatitis C poses a serious health problem for those incarcerated,
because many inmates already have the virus, and Hepatitis C is the most common
type of hepatitis in jails and prisons. 50 Accordingly, the CDC recommends universal

40

Id. (See also IVLwo CLINIC, IVLwo MEDICAL LABORATORIES, Test ID: HCVL, Hepatitis C
Virus Antibody Confirmation, Serum, http://v1l\¥W.mayomedicallaboratories.com/test-catalog/
Overview/63063, (last visited on Jan. 30, 2017).
41

Id.

42

NATIONAL RESEARCH COUNCIL OF THE NATIONAL ACADEMIES, The Growth
in the
United States: Exploring Causes and Consequences, Chapter 9, Pg. 221 (2014). https://wv</\v.nap.

edu/read/18613/chapter/9#22 l
43

44

Id.
See Management ofHepatitis C in Jails versus Prisons, CENTER FOR DISEASE CONTROL AND

PREVENTION (Jan. 4, 2017), http://wVl!\V.hepatitisc.uw.edu/pdf/special-populations-situa1ions/
treatment-corrections/core-concept/all (noting that a person is jailed upon arrest for allegedly
committing a crime. Most states will hold individuals in jail for sentences up to 1 year, although this
may be extended to include longer sentences. Jails are typically operated and funded by local cities
or counties, whereas prisons are part of either a state or federal system, and house persons convicted
of felonies.)
4s

Id.

46

See HEPATITIS c AND INCARCERATION, supra note 24.

47

Varan et al.Hepatitis C SeroprevalenceAmong Prison Imnates Since 2001: Still High but
Declining. Public Health Reports, 2014; 129: 187-195

49

Id. (citing Varan et al.Hepatitis C SeroprevalenceAmong Prison Inmates Since 2001: Still High
but Declining. Public Health Reports, 2014; 129: 187-195.).

so Id.
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Hepatitis C screening for all incarcerated inmates. 51 The National Hepatitis Corrections
Network states that high prevalence of Hepatitis C within the prison system may
also be attributable to the populations who are most affected by incarceration (such
as the poor, injection drug users, and the mentally ill), who are more likely to have
Hepatitis C52 . The most common ways inmates transmit Hepatitis C include sharing
equipment used for injecting drugs, tattooing and piercing with those individuals that
are already infected with the virus. 53 Since correctional health facilities pose a high
risk for contracting the virus, the CDC recommends counseling and testing to prevent
spreading the infection. 54

II. STANDARD OF MEDICAL CARE
A. Treatment Options for Hepatitis C
Due to recent medical developments, if a person today is diagnosed with Hepatitis C,
it no longer means months and months of painful drug injections, which was the only
treatment option available for decades. 55 Science is continually developing new means
and methods for treating all medical diseases and illnesses, the treatment for Hepatitis
C is no different. 56 In fact, science has made leaps and bounds in the development for a
cure. 57 The first "curing" oral treatment regimen (Sovaldi) was approved by the FDA late
in December, 2013. 58 Today, there are even more mediations that have been approved
by the FDA to treat the various genotypes of Hepatitis C, and have been proven to have
successful cure rates. 59
51
Management ofHepatitis C in Jails versus Prisons, http://www.hepatitisc.uw.edu/pdf/specialpopulations-situations/treatment-corrections/core-concept/all
52

Nat's Hetatitis Corrections Netrowk, An Overview ofHepatitis C in Prisons and Jails,
(0212212016), http://www.hcvinprison.org/resources/7 l -main-content/content/ 191-hepcprison

53

Id

54

See generally CENTERS FOR DISEASE CONTROL AND PREVENTION, US. DEP'T OF HEALTH AND HuMAN
SERVICES, MMWR No. 47RR-19, RECOMMENDATIONS FOR PREVENTION AND CONTROL OF HEPATITIS C
VIRUS (HCV) INFECTION AND HCV-RELATED CHRONIC DISEASE, (1998), https://www.cdc.gov/mmwr/
preview/mmwrhtml/00055154.htm.
55

See FDA Consumer Updates, supra note 5.

56

See generally Anne Harding, Pros and Cons of New Hepatitis C Drugs, EVERYDAY HEALTH, http://
www.everydayhealth.com/news/pros-cons-new-hepatitis-treatments-patients/ (page last updated:
April 7, 2015); American Liver Foundation, Advances in Medication to Treat Hepatitis C, (October
2016), http://hepc.liverfoundation.org/treatment/the-basics-about-hepatitis-c-treatment/advances-inmedications/
57

American Liver Foundation, Can hepatitis C Be Cured?, (October 2016), (The Hepatitis C virus
is considered cured if the virus is not detected in your blood 3 months after treatment is completed)

58

Id (Sovaldi (sofosbuvir)), a once-daily pill, was approved to treat HCV genotypes 1, 2, 3 and 4.
This was the first drug that allowed genotype 2 and 3 patients to be treated with pills only, offering
an interferon-free regimen with ribavirin.
59
American Liver Foundation, Advances in Medication to Treat Hepatitis C, (October 2016),
http ://hepc. liverfoundation. mg/treatment/the-basics-about-hepatitis-c-treatment/advances- inmedications/ (Harvoni, which is a once-daily pill that combined sofosbuvir (Sovaldi) and a new drug
called ledipasvir was approved in October, 2014; In November, 2014, the FDA granted simeprevir
(Olysio) an additional approval to be used in combination ¥.':ith sofosbuvir (Solvaldi) as a once-daily,
all-oral, interferon and ribavirin-free treatment for adults with genotype 1 HCV infection. This
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Prior to 2013, Interferon-based injections were the only option for treatment. 60 Interferon
was approved in the 1990s, and when later combined with Ribavirin (another drug that
fights the virus) the cure rate jumped from less than 5% in the 1980s to about 50% by
the early 2000s. 61
However, Interferon and Ribavirin cause many side effects including muscle aches,
fever, nausea, anxiety, and trouble sleeping. 62 These medications often need to be taken
for forty-eight weeks to see results, and in some instances have required taking the
regimen for up to a year without results. 63
In 2011, the United States Food and Drug Administration (FDA) approved two new
drugs: boceprevir (Victrelis) and telaprevir (Incivek), which stop the virus from
making a copy of itself. 64 Combining telaprevir or boceprevir with interferon and
ribavirin pushed success rates as high as 70%. 65 However, the drug combination still
was not ideal; as the additional drugs increased so did the side effects. 66 In 2013 and
2014, the FDA approved three new drugs: (1) Simeprevir (Olysio), (2) Sofosbuvir
(Sovaldi), and (3) Ledipasvir-sofosbuvir (Harvoni). 67 The combination of Simeprevir
with interferon and ribavirin clears the Hepatitis C virus in up to 80% of people who
take it. 68 According to the FDA, Ledipasvir-sofosbuvir can be taken without interferon
and ribavirin. 69 Sofosbuvir can also be used without interferon for people with some

approval gave people with genotype 1 another all-oral treatment option; December, 2014, the FDA
approved a new combination medicine called Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets;
dasabuvir tablets), which can be given with or without Ribavirin, to treat adults with genotype 1
infection; then in July, 2015, the FDA approved two new drugs - Technivie for the treatment of
genotype 4 and Daklinza for the treatment of genotype 3. Further developments were approved in
2016, with Zapatier ((elbasvir 50 mg/grazoprevir 100 mg) being approved in January to treat adults
with chronic HCV genotypes 1 or 4 infection, including those with compensated cirrhosis, HIV-1
co-infection, or severe kidney disease and on dialysis, and most recently in June, 2016, Epclusa
(sofosbuvir 400mg/velpatasvir 100 mg) which is a new combination medicine, was approved to treat
genotypes 1, 2, 3, 4, 5, or 6. It is also the first single tablet regimen approved for the treatment of
patients with HCV genotype 2 and 3, without the need for ribavirin.) (October, 2016).
60 See FDA Consumer Updates, supra note 5. See also American Liver Foundation, Advances in
Medication to Treat Hepatitis C, (October 2016), http://hepc.liverfoundation.org/treatment/thebasics-about-hepatitis-c-treatment/advances-in-medications/ (last visited Feb. 8, 2017)
61 U.S. Dept. of Veterans Affairs, Interferon and Ribavarin Treatment Side Effects, TOPIC REVIEW,
http://www.hepatitis.va.gov/provider/reviews/treatment-side-effects.asp (page last updated: Aug. 26,
2016).
62 Id.
63 U.S. Dep't ofVeteranAffairs, Hepatitis C Genotypes and Quasispecies, TOPIC REVIEW (2005),
http://www.hepatitis.va.gov/provider/reviews/genotypes.asp.
64 Alan Francisus, A Brief History ofHepatitis C, 4.3 HCV Advocate 1, 5-6 (2015), http://
hcvadvocate.org/hepatitis/factsheets_pdf/Brief_History_HCV pdf.
6s Id.
66

Id.

67

Id.

68

Id.

69

ld.
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types of Hepatitis C. 70 Sofosbuvir, which seems to be the most ideal choice for a cure,
comes in an easy once-a-day pill. 71 It takes as few as twelve weeks to work, and has a
cure rate of up to 90%. 72
In January 2014, the Infectious Disease Society of America and the American
Association for the Study of Liver Disease issued guidelines recommending treatments
by genotype, including prescribing sofosbuvir and similar drugs as the first line of
therapy to replace Interferon injections entirely. 73 The HCV Guidance has since been
updated to reflect developments and FDA approvals as of July 6, 2016. 74 Recent
clinical trials with the breakthrough drugs (instead of interferon), have been found to
have even higher rates of "virologic success" and fewer side effects, 75 which should
lead to even more widespread success. 76
All of these new drugs allow a shorter treatment span without injections and produce a
higher cure rate. 77 There is no wonder that many people diagnosed with the disease want
to have access to them. This has recently prompted the filing of class action lawsuits from
prison inmates alleging that they have been denied access to "adequate" medical care, in
violation of their Constitutional rights under the Eighth and Fourteenth Amendments. 78
B. Just What Does This Cure Cost?
One can easily say that the new drugs are not cheap. The cost is a daunting $84,000
for a 12-week course of Sofosbuvir, or approximately $1,000 per pill. 79 Even with
this high price, prison providers are starting to use this next generation of agents, in
certain instances. 80
70

See Francisus, supra note 64.

71

See American Liver Foundation, supra note 63

72

Id.

73

American Association for the Study of Liver Diseases and Infectious Diseases Society of
America (AASLD), HCV Guidance: Recommendations for Test, Managing and Treating Hepatitis
C, http://hcvguidelines.org/ (last visited Feb. 8, 2017).
74

Id. See http://hcvguidelines.org/full-report/initial-treatment-box-sunuuary-recommendationspatients-who-are-initiating-therapy-hcv for the latest recommendations for patients who are
initiating therapy.
75
See
Kowdley et al., Lawitz E, Ledipasvir and Sofosbuvir for 8 or 12
chronic
HCV without cirrhosis, 370(20) N Engl J Med. 1879 (2014), http://www.nejm.org/doi/pdf/10.1056/
NEJMoa1402355.
76
See Feld et al., Treatment ofHCV with ABT-450/Rombitasvir and Dasabuvir with Ribavirin. 370
N Engl J Med. 1594 (2014), http://www.nejm.org/doi/pdf/10.1056/NEJMoal315722.

77

See American Liver Foundation, supra note 63

78

See Chimenti v. Pennsylvania Dept. of Corrections, No. 15-3333, 2016 U.S. Dist. LEXIS 36682
(E.D. Pa. Mar. 21, 2015); Paszko v: O'Brien, No. 1-15-cv-12298-NMG (D. Mass. June 10, 2015);
Ligons v. Minnesota Dept. of Corrections, No. 15-cv-02210-PJS-BRT (D. Minn. filed May 1, 2015).
79
Charles Ornstein, New Hepatitis C Drugs are Costing lv!edicare Billions, THE WASH. PosT
(March 29, 2015), https://W\vw.washingtonpost.com/national/health-science/medicare-spent-45billion-on-new-hepatitis-c-drugs-last-year-data-shows/20 l 5/03/29/66952dde-d3 2a-1 l e4-a62fee74591 l a4ff_story.html.

so Federal Bureau of Prisons, Interim Guidance for the _Management of Chronic Hepatitis C
Infection, (2014 ), http://W\vw.bop.gov/resources/pdfs/hepatitis_c_current.pdf.
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Other government-managed programs like Medicaid and Medicare are still working
out the standards for people who want to take the new medications. 81 The Washington
Post reported that Medicare spent over $4.5 billion dollars of federal taxpayer money
on treating Hepatitis C alone, which included the elevated costs for the newly approved
drugs. 82 Medicaid on the other hand was much more restrictive with providing the
drugs, and often required the patients to have advanced liver disease to be eligible for
the newly approved pills. 83 However, it is reported that Medicaid acknowledges that
"anticipated legal challenges may compel state Medicaid programs to stop rationing
the new drugs." 84 As the prison systems are also publicly funded, the high cost of these
drugs could have detrimental effects on Department budgets, in the event that they are
required to pay for the treatment of all inmates 85 . In fact, the new treatment options
could costs six to eight times more than prescribing Interferon. 86
Recent reports show that despite the high costs of treatment, some prison systems are
offering the new drugs to inmates, 87 the most notable is the Federal Bureau of Prisons. 88
However, the Federal Bureau of Prisons, which oversees the federal prison system, is
reported to be receiving a 44% discount on the new drugs, enabling it to provide the
treatment to inmates. 89
C. How Will This Cure Affect Correctional Facilities?

In order for the United States to effectively eliminate Hepatitis C, this would require
providing treatment to prisoners. As described above, there is an overwhelming
percentage of inmates who currently have Hepatitis C, and the cost of treating and
curing this disease is expensive. At costs of approximately $84,000 per person, without

81

Medicaid.gov, Keeping America Heathly, HCV Communication, https://www.medicaid.gov/
medicaid/prescription-drugs/hcv/index.html(last visited Feb. 8,
Ornstein, supra note 79.
82

Id.

83

Id.

S4

Id.

85

Peter Loftus and Gary Fields, High Cost
C Drugs Strains Prison
Locks
Many Out
The Wall Street Journal, September 12, 2016, https://www.wsj.com/articles/highcost-of-new-hepatilis-c-drugs-strains-prison-budgets-locks-many-out-of-cure-1473701644
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any discount such as that which the Veterans Affairs or the Federal Bureau of Prisons
is reported to receive - this cure would potentially undermine the Department of
Corrections' budgets. 90 Recent reports indicate that it would take an estimated $33
billion dollars to treat all of the incarcerated people, which is more than four times the
total health spending by state prison systems. 91
Although United States prisons offer routine screenings for HIV, not all prisons offer
screenings for Hepatitis C, which may provide an explanation for the spreading of the
virus within the prisons. The Federal Bureau of Prisons published an Interim Guidance
for the Management of Chronic Hepatitis C Infection in June, 2014. 92 This guideline
specifically acknowledges the advancing treatments and rapidly changing clinical
guidelines with the progression of science. 93 The guideline sets forth a prioritized
treatment plan beginning with those diagnosed with advanced stages of the virus and
liver transplant recipients, then moving down the list to inmates that are also HIV coinfected, and lastly to those newly incarcerated inmates who were being treated at the
time of incarceration. 94 Perhaps the most on target issue can be found in the guideline
outlining the recommended treatment regimens. 95 Although the treatment is evaluated
on a case-by-case basis, the "Preferred regimen" is the sofosbuvir + ribavirin 12-week
program. 96 The guideline also specifically categorizes treatment regimens that are no
longer recommended, which includes Interferon, unless an inmate is completing a
course of treatment that has already been started with Interferon. 97
Prisoners have a constitutional right to healthcare, even beyond that of the general
population. 98 This right falls within the Eighth and Fourteenth Amendments, and
requires the correctional facilities to provide adequate medical care. 99 Estelle v.
Gamble established that the Eight Amendment "imposes duties on [prison] officials,
who must ... ensure that inmates receive adequate ... medical care, and must 'take
reasonable measures to guarantee the safety of the inmates."' 100
With the excessive costs of treatment, correctional facilities have yet to provide this
treatment for all individuals diagnosed with the disease, but instead have tried to focus
on those with advanced stages of the disease, and the duration an inmate will be in
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custody. 101 Within the last year, class action lawsuits in three states have been filed
to put pressure on the correctional facilities to provide these new drugs, which may
provide a cure for Hepatitis C. These class actions were filed on behalf of prisoners
in Minnesota, Pennsylvania and Massachusetts. 102 These suits were brought under the
Eighth and Fourteenth Amendments under the United States Constitution, for which
42 U.S.C. § 1983 provides declaratory, equitable and legal remedies. 103 The complaints
also include allegations under Title II of the Americans with Disabilities Act as
Amended and §504 of the Rehabilitation Act of 1973. 104 Jurisdiction is argued by the
plaintiffs in those suits to be established under both a federal question and a federal
civil rights question. 1os
The complaints filed in each of these three cases set out the same basic principles: (1)
the prisoners suffer from serious medical need, disability and a life-threatening viral
disease known as Hepatitis C, (2) the acknowledgement of the FDA "breakthrough"
drugs twelve week daily-pill therapy protocol approved to cure Hepatitis Cat a 95% rate
as the community standard of care, and (3) the failure, through non-medical reasons on
the defendants' part 106 to provide the community standard of care to cure inmates and
prevent the spreading of this infectious disease. 107 The non-medical reasons argued by
the plaintiffs include: (1) the administrative convenience, (2) cost, and (3) correctional
policies designed to ration medication to a limited number of inmates. 108 The lawsuits
state that the Federal Bureau of Prisons, the CDC, the United States Public Health Service
(Surgeon General), the FDA, and the United States Department ofVeteransAffairs (VA)
have all recognized this twelve week treatment program as the new standard of care
within the medical community for the treatment of Hepatitis C. 109
In all three pending class action lawsuits, the various departments of corrections have
filed similar answers raising parallel affirmative defenses. In response to the complaint
filed by inmates, the Minnesota Department of Corrections asserts the following
affirmative defenses in its Answer: (1) failure to state a claim under 42 U.S.C. § 1983; (2)
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claims may be barred by the statute oflimitations; (3) claims may be barred by qualified
immunity and the Eleventh Amendment; (4) sovereign immunity, official immunity,
vicarious official immunity, statutory immunity and/or discretionary immunity; (5) such
damages and/or injuries are the result of the plaintiff's own conduct and actions and/or
actions of third person(s) over whom the Department of Corrections exercises no control;
(6) the damages were caused by risks known to or primarily assumed by the plaintiffs;
(7) plaintiffs' damages were the result of a natural disease process, pre-existing medical
conditions, pre-existing medical disabilities, a superseding cause, an act of nature and/
or the act or omission of persons over whom the Department of Corrections does not
have control; and (8) the Department's actions or conduct was authorized by law, was
reasonable and was taken in good faith. 110
In her Answer, Commissioner Higgins O'Brien admits that over 1,500 patients in the
custody of the Massachusetts Department of Correction are known to have Hepatitis
c.rn The Massachusetts Partnership for Correctional Healthcare, LLC's Answer
contains similar defenses to those raised by the Minnesota Department of Corrections,
listed above. One distinct difference raised in Massachusetts Partnership's answer is
that the defendants' actions do not rise to the level of a constitutional violation; and
therefore, the plaintiffs cannot recover. 112 Defendants specifically note that they were
not deliberately indifferent to the serious medical needs of the inmates. 113
In Chimenti v. Pennsylvania Dept. of Corrections the Department of Corrections has
filed a Motion to Dismiss based on a failure to state a claim and a Motion to Sever. The
Department's Motion to Dismiss was granted in part and denied in part. The motion was
granted pursuant to certain counts alleged against certain Defendants named in the suit;
however, the Motion to Dismiss was denied in all other respects. 114 Additionally, the
Motion to Dismiss and Sever filed by the Medical Defendants was granted in part and
denied in part. 115 The granted portion of the motion pertained to the claims asserted in
Count I against Defendants Andrew Dancha, Dr. John Hochberg, Dr. Nicholas Scharff,
Dr. Thomas Lehman, and Correct Care Solutions, which count has been dismissed
against the above referenced Defendants. 116
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A series of articles have been published bringing national attention to the issue of whether
prison authorities have the right to deny prisoners life-saving medical care based on the
price tag of treatment. 117 Although the price tag of the curing treatment is an issue raised
by the inmates, the specific issue that the courts will have to answer in these class action
suits, which will set precedent for the Department of Corrections nationwide, is whether
the Department of Corrections is required to provide the latest standard of care to avoid
a constitutional violation of failing to provide adequate care to inmates.

III. JUDICIAL SOLUTION
A. How Should The Courts Address This Matter?

Section 1983 provides remedies for deprivations of rights established in the Constitution
or federal laws. 118 42 U.S.C. § 1983 provides, in pertinent part:
Every person who, under color of any statute, ordinance, regulation, custom, or usage,
of any State ... , subjects, or causes to be subjected, any citizen of the United States or
other person within the jurisdiction thereof to the deprivation of any rights, privileges,
or immunities secured by the Constitution and laws, shall be liable to the party injured
in an action at law, suit in equity, or other proper proceeding for redress ... 119
To establish a 42 U.S.C. § 1983 claim, a plaintiff must demonstrate (1) that he has
been deprived of a right secured by the Constitution and laws of the United States;
and (2) that the alleged deprivation was committed by a person acting under color of
state law. 120
All three class action complaints allege, the Department of Corrections, through its
officials and medical providers, have violated these prisoners' rights under the Eighth
Amendment to be free from cruel and unusual punishment. A prisoner's treatment and
the conditions of imprisonment are subject to EighthAmendment scrutiny. 121 However,
courts have held that "the duty to provide a certain level of health care to incarcerated
offenders under the Eighth Amendment is a limited one." 122 "Not 'every ache and
pain or medically recognized condition involving some discomfort can support an
Eighth Amendment claim."' 123 The United States Supreme Court has found that a
117
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"deliberate indifference to serious medical needs of prisoners violates the [Eighth]
Amendment because it constitutes the unnecessary and wanton infliction of pain
contrary to contemporary standards of decency." 124 Thus, a plaintiff must show both
"deliberate indifference" and a "serious medical need." 125 The first test is subjective,
the second is objective. 126
A plaintiff must show that the defendant knew of a substantial risk of serious harm to the
plaintiff and still refused medical assistance. 127 The official must "both be aware of facts
from which the inference could be drawn that a substantial risk of serious harm exists,
and he must also draw the inference." 128
[The test for deliberate indifference] affords considerable latitude to prison medical
authorities in the diagnosis and treatment of medical problems of inmate patients.
Courts will 'disavow any attempt to second-guess the propriety or adequacy of a
particular course of treatment .. . [which] remains a question of sound professional
judgment.' Bowring v. Godwin, 551 F.2d 44, 48 (4th Cir.1977). Implicit in this
deference to prison medical authorities is the assumption that such an informed medical
judgment has, in fact, been made. When, however, prison authorities prevent an inmate
from receiving recommended treatment for serious medical needs or deny access to a
physician capable of evaluating the need for such treatment, the constitutional standard
of Estelle has been violated. 129
Questions of medical judgment, disagreement between an inmate and medical personnel
regarding diagnosis and course of treatment, and mere malpractice do not constitute
deliberate indifference. 130 However, a delay in medical treatment may constitute
deliberate indifference. 131 A constitutional violation only occurs if the delay results in
some "substantial harm" to the patient. 132
In addition to "deliberate indifference," the plaintiff must also show that such
indifference was directed to a "serious medical need." 133 Because society does not
expect that prisoners will have unqualified access to healthcare, ' a prisoner must first
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make [a] threshold showing of serious illness or injury" to state a cognizable claim. " 134
On the other hand, courts have recently held that when deliberate indifference relates
to medical care "[t ]he requirement of deliberate indifference is less stringent ... than in
other Eighth Amendment contexts because the responsibility to provide inmates with
medical care does not generally conflict with competing penological concerns." 135
Generally, deliberate indifference to serious medical needs may be manifested in
two ways: "when prison officials deny, delay, or intentionally interfere with medical
treatment, or ... by the way in which prison physicians provide medical care." 136 The
Tenth Circuit has found that prison officials may be liable for an Eighth Amendment
violation for "indifference ... manifested ... in their response to the prisoner's needs
or by .. . intentionally denying or delaying access to medical care or intentionally
interfering with treatment once prescribed." 137
"Serious medical needs" are those diagnosed by a physician as mandating treatment or
those that are so obvious that even a lay person would easily recognize the necessity for
a doctor's attention. 138 Courts have found a serious medical need "if the failure to treat
the prisoner's condition could result in further significant injury or [if] [there] [is] the
'unnecessary and wanton infliction of pain'" it may qualify as a serious medical need. 139
Indications may include "[t ]he existence of an injury that a reasonable doctor or patient
would find important and worthy of comment or treatment; the presence of a medical
condition that significantly affects an individual's daily activities; or the existence of
chronic and substantial pain." 140
In addition to demonstrating that the medical need is objectively serious, the plaintiff
must also show that the delay in the provision of medical care resulted in objectively
"substantial harm" in order to establish an Eighth Amendment violation. 141 "The
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substantial harm requirement may be satisfied by lifelong handicap, permanent loss, or
considerable pain." 142
Courts have recently upheld the notion that Hepatitis meets the requirement of being an
objectively serious medical condition. 143 Therefore, the main hurdle that plaintiffs will
face in these recent suits is establishing the subjective test of deliberate indifference.
The Sixth Circuit has recently held that for a corporation to act with the requisite level
of subjective intent, it must do so through its policies and customs. 144 This notion was
directly applied in the context of a correction facility. The court found that "[p ]laintiff
must allege that the employees acted in accordance with some official policy or custom
of [the Department of Corrections], or that [the Department of Corrections] encouraged
the specific misconduct or in some way directly participated in it." 145 Although the case
was dismissed for failure to state a claim, it was filed in the context of an inmate alleging
an Eighth Amendment violation for the failure of a correctional facility to provide the
drug Sovaldi to treat the inmate's Hepatitis C.
The most relevant finding of the Sixth Circuit Court is as follows: 146
[t]he question is not whether a prisoner is receiving the medication or treatment of his
choosing, or whether he is receiving the best health care available for his condition.
Instead, the inquiry for Eighth Amendment purposes is whether the course of treatment
he is receiving is "so grossly incompetent, inadequate, or excessive as to shock the
conscience or to be intolerable to fundamental faimess." 147 The relevant inquiry
to determine whether the Defendant provided grossly inadequate care is "whether a
reasonable doctor ... could have concluded his actions were lawful." 148
Although the representatives in the class actions lawsuits have set forth advanced stages
of the virus, recent case law may foreclose relief to those who cannot show such advanced
stages. 149 The Tennessee Department of Corrections recently prevailed over an inmate's
claim alleging that he was denied medical care, even though the facility was aware
that he tested positive for the Hepatitis C. 150 The plaintiff in that case was diagnosed
with Hepatitis C, Genotype 1. 151 The court focused on the primary indicator of whether
treatment of Hepatitis C is warranted as being the regular and consistent monitoring
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of liver enzyme levels, specifically the SGOT/AST and SGPT/ALT levels. 152 Both of
these tests indicate specific liver enzyme production or a lack thereof. 153 The Tennessee
Department of Corrections implemented a policy where all inmates in custody, who have
been diagnosed with Hepatitis C, are monitored for increased liver enzyme levels on a
regular basis. 154 They are also assessed by physical exam to evaluate for any symptoms
at regularly scheduled intervals. 155
The plaintiff's medical records show that lab work has been conducted at least thirteen
times since January, 2013. 156 The latest lab work revealed that the plaintiff's liver was
functioning normal, and in the same range as individuals who did not have Hepatitis
C. 157 Additionally, the plaintiff's liver enzyme levels indicated that his liver was not in
active cirrhosis. 158 Since the plaintiff's Hepatitis C was stable and he was not in any way
in an acute phase, the court found that the Department's general policy of monitoring
enzyme levels at least every three months for all inmates diagnosed with Hepatitis C was
sufficient, because the policy was consistent with generally accepted medical practices,
regardless of whether the patient was incarcerated or not. 159
The Garrison case limited relief available to an inmate and did not require the Tennessee
Department of Corrections to provide the latest drug breakthrough to all inmates, unless
they could show the medical standard of care for the level of advanced virus they have.
This holding is consistent with Graham v. Wright where a prisoner complained of delay
in providing treatment for Hepatitis C. 160 In Graham the court held that the objective
element of deliberate indifference standard must be satisfied by "harm that resulted
from the delay." 161
Further, the CDC has found that not everyone requires treatment or can benefit from
treatment. 162 This determination should be made by after being checked by a doctor
experienced in treating chronic Hepatitis C. 163 He or she can determine the most
appropriate medical care. 164 Decisions about starting treatment are based on many
factors, such as the type of virus, the condition of the liver, and other health conditions. 165
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In expanding beyond a determination of each individual on a case-by-case basis, the
issue of adequate medical care versus the community standard of medical care has
directly been addressed across the jurisdictions. In October 2015, the United States
District Court for the Central District of California specifically found that "the Eighth
Amendment does not require optimal medical care or even medical care that comports
with the community standard of medical care." 166 This same concept has been upheld in
the District of Nevada by finding "[o]nly where the prison's chosen course of treatment
is 'medically unacceptable under the circumstances' are the officials' medical choices
constitutionally infirm." 167
Additional case law from the Eastern District of Wisconsin168 has held:
[t]o establish deliberate indifference, the prisoner must demonstrate "that the treatment
he received was 'blatantly inappropriate,"' id. (quoting Greeno v. Daley, 414 F.3d 645,
654 (7th Cir.2005)); or, stated another way, that the treatment decision "represents
so significant a departure from accepted professional standards or practices that it
calls into question whether the [medical professional] was actually exercising his
professional judgment," id. (citing Roe v. Elyea, 631 F.3d 843, 857 (7th Cir.2011)
and Sain v. Wood, 512 F.3d 886, 895 (7th Cir.2008)); Gayton, 593 F.3d at 622-23.
(Emphasis added).
However, because there is more than one treatment option for Hepatitis C, which may
be determined based on a number of factors presented by each individual, New York
courts have held that determinations specifically pertaining to the treatment of Hepatitis
C and compliance with "[Department of Correctional Services] Guidelines, reflect
medical judgments, not 'deliberate indifference' under the Eighth Amendment." 169
Additionally, the Third Circuit recently held that in making the determination of
prescribing certain drugs or treatment, the Eighth Amendment does not completely bar
medical professionals and healthcare administrators from considering cost as a factor
when evaluating treatment options. 170
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IV.AN ANALYSIS OF THE WYOMING STATE POLICY AND
POTENTIAL IMPLICATIONS
This section will provide an illustration of the Wyoming Department of Corrections
health policy as it relates to Hepatitis C, and is intended only to serve as an practical
example. The Wyoming Department of Corrections currently has a policy and
procedure that provides for health screens and a health appraisal of all inmates. Policy
4.305(11) provides:
A.

Health Screens. It is the policy of the WDOC that all inmates receive an intake
health screen performed by health-trained or qualified health care personnel
upon arrival to WDOC facilities and that all findings of these health screens
are recorded on a screening form approved by the health authority.

B.

Health Appraisal. It is the policy of the WDOC that all inmates (excluding
intra-system transfers) receive a comprehensive health appraisal, unless
there is documented evidence of a health appraisal within the previous
ninety (90) days. 171

Under this policy, health screens shall be performed within the first few hours of arrival. 172
The screenings should include an inquiry into any past history of serious infectious
communicable illnesses and medications, current illnesses and health problems which
specifically include communicable diseases, encompassing Hepatitis C. 173 Under the
requirements for the health appraisal, the facility staff and the qualified health care
professionals shall perform laboratory and/or diagnostic tests to detect communicable
diseases within seven days of arrival. 174
The Wyoming Department of Corrections has even gone one step further and
implemented an Exposure Control Plan to protect staff members and inmates from
blood-borne pathogens. 175 The plan identifies and addresses the following criteria:
"individuals and types of contact, precautions, protection, handling, housekeeping,
proper disposal and training of individuals." 176 This plan is specifically designed to meet
federal, state and local regulations and guidelines with an emphasis on the Wyoming
Occupational Safety and Health Rules and Regulation as they apply to correctional
facilities. 177 This policy further requires that the contracted medical service providers
create and implement procedures to comply with this policy, OSHA standards and
the Department of Correction's standards. Lastly, the Department of Corrections has
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implemented a policy addressing the management of Hepatitis C, including procedures
for when and where inmates are to be tested/screened and under what conditions inmates
are to be separated from the general population. 178 The only concerning implication is
the testing of inmates. Under Policy and Procedure # 4.312(B)(5), inmates shall be
tested if they show symptoms associated with the disease; whereas the testing for HIV
is mandatory during the initial screening of all inmates. 179

CONCLUSION
Hepatitis C poses a substantial risk not only to prisoners, but also to the general
population. Statistics show that at least "95% of all state prisoners will be released from
prison at some point." 180 However, just as any medical professional would examine
each patient diagnosed with cancer individually, the same concept should be applied to
those diagnosed with Hepatitis C. Because the disease affects each person differently,
and advances at different intervals in every person diagnosed, medical care should be
provided to inmates just as it would be to the general community population. In the
event that the newly approved curing treatment is found to be the accepted professional
standard or practice of care for all stages of the disease, then such treatment would be
required to be provided to not only inmates diagnosed with Hepatitis C, but also to all
individuals contracted with Hepatitis C. However, at this time, this is not the current
practice or professional standard. Because a treating physician evaluates numerous
factors to determine the appropriate method of treatment, including the cost of such
treatment, the advanced stage of the disease, and each patient on a case-by case bases;
the current class actions should not succeed in seeking to have the latest development in
drugs for treating Hepatitis C made available to every prison inmate. Finally, because the
latest recognized standard of care drugs are not required to provide "adequate" medical
treatment to satisfy the Eight Amendment, absent a diagnosis of an advanced stage of
Hepatitis C, the states' Department of Corrections should not be mandated to provide
this costly treatment to inmates, and the class actions should not prevail.
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